Company / Operating Cash Flow per Share
Aclaris Therapeutics, Inc. Operating Cash Flow per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.44
FY2025
5-year range
-$1.16 / -$0.44
FY2021-FY2025
Trend
+60.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 9 years, ranging from $-3.27 in FY2018 to $-0.44 in FY2025.
Based on SEC 10-K filings.
-0.44 in FY2025.
Improved from $-0.78 to $-0.44 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 60.5% year-over-year.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.44 | +60.5% |
| FY2024 | -$1.10 | -41.3% |
| FY2023 | -$0.78 | +29.2% |
| FY2022 | -$1.10 | +4.5% |
| FY2021 | -$1.16 | +52.4% |
| FY2020 | -$2.43 | -83.2% |
| FY2019 | -$1.33 | +59.4% |
| FY2018 | -$3.27 | -318.0% |
| FY2017 | -$0.78 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026